The new generation of domestically produced antiviral oral medication for the flu has been launched on the market.

On July 18, the official website of the State Drug Administration showed that the influenza antiviral oral medication Masitinib hydrochloride tablets have been approved for marketing, used to treat uncomplicated influenza A and B in previously healthy adults, excluding patients at high risk of influenza-related complications. Masitinib hydrochloride is a new generation of polymerase acidic protein nucleic acid endonuclease inhibitor independently developed by Chengxiang Medicine, with broad-spectrum antiviral properties against influenza viruses, including influenza A and B viruses, highly pathogenic avian influenza viruses, etc.